生物科技公司Latigo Biotherapeutics(LTGO)今日盘中大涨16.67%，成为市场焦点。该股今日在纳斯达克首日上市，开盘后股价迅速走高，表现强劲。
此次股价大涨主要得益于Latigo规模扩大的首次公开募股(IPO)获得市场热烈响应。公司以每股18美元的价格发行1920万股，最终发行价位于16至18美元指导区间的高端，发行规模较原计划增加了27%，共筹集资金3.456亿美元。在正式开盘前，该股已显示开盘价有望达到20美元，较发行价高出约11%，显示出投资者对其的强烈需求。
Latigo专注于开发非阿片类止痛药物，其核心候选药物LTG-001是一款口服Nav1.8抑制剂，旨在为急性疼痛提供起效迅速且无成瘾风险的缓解方案，已展现出优于现有疗法的临床数据。此外，公司上市正值生物科技板块IPO的黄金窗口期，2026年以来美国生物科技和制药企业IPO加权平均回报率高达55%，市场对具备差异化临床数据和明确市场机会的平台型公司兴趣浓厚，为Latigo的股价表现提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.